ABSTRACT
Pimavanserin(Nuplazid) is a drug of selective targeting 5-HT2A receptor,developed by Acadia Pharmaceuticals. In April 29,2016,it was approved by FDA for the treatment of Parkinson′s disease(PD)patients experiencing mental symptoms such as hallucinations and delusions. In this paper,we summarize the synthetic methods of pimavanserin published in literature in re?cent years and their advantages and disadvantages.
ABSTRACT
Pimavanserin(Nuplazid) is a drug of selective targeting 5-HT2A receptor, developed by Acadia Pharmaceuticals. In April 29, 2016, it was approved by FDA for the treatment of Parkinson’s disease (PD) patients experiencing mental symptoms such as hallucinations and delusions. In this paper, we summarize the synthetic methods of pimavanserin published in literature in recent years and their advantages and disadvantages.